NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Viyash Scientific Q3 FY26 EBITDA Jumps 64% YoY; Margins Expand to 21.6% on Merger Synergies
Viyash Scientific reported a strong Q3 FY26 with consolidated revenue growing 11% YoY to ₹8,584 million. The company's EBITDA saw a significant jump of 64% YoY to ₹1,854 million, driven by a 690 bps margin expansion to 21.6%. Net debt levels improved substantially, with the Net Debt to LTM EBITDA ratio falling to 0.4x from 1.2x a year ago. This quarter marks the first time results are announced for the merged entity, showcasing early benefits from R&D and manufacturing synergies.
முக்கிய அம்சங்கள்
Consolidated revenue reached ₹8,584 million in Q3 FY26, an 11% YoY increase.EBITDA surged 64% YoY to ₹1,854 million, with margins improving to 21.6% from 14.6%.Net Debt to LTM EBITDA ratio improved to 0.4x, down from 1.2x in Q3 FY25.Formulations segment grew 20% YoY to ₹4,809 million, while API business grew 3% to ₹3,658 million.Exceptional costs of ₹413 million were incurred due to merger-related stamp duty and professional fees.
👀 கவனிக்க வேண்டியவை
The significant margin expansion and debt reduction post-merger signal strong operational efficiency and synergy realization. Investors should monitor the company's ability to maintain these margins as it scales its CDMO and companion animal portfolios.
Viyash Scientific Reports Q3 Revenue of ₹8,584M and Announces Key Management Changes
Viyash Scientific Limited (formerly Sequent Scientific) reported a consolidated revenue of ₹8,584 million for Q3 FY26, showing steady growth from ₹8,503 million in the previous quarter. The company has restructured its senior management team, appointing new VPs for R&D and Quality to align with post-merger strategic objectives. Net profit for the quarter stood at ₹485.20 million, which was significantly impacted by one-time merger-related exceptional expenses of ₹412.60 million. The board also approved a new 2026 ESOP scheme to incentivize leadership following the successful amalgamation of multiple entities.
முக்கிய அம்சங்கள்
Consolidated revenue for Q3 FY26 reached ₹8,584 million compared to ₹8,503 million in Q2 FY26.Profit After Tax (PAT) stood at ₹485.20 million, affected by ₹412.60 million in exceptional merger costs.Appointed three new Senior Management Personnel (SMP) in R&D, Quality, and COO roles for subsidiaries.Completed the allotment of 18.19 crore equity shares as part of the composite scheme of amalgamation.Approved the 'Viyash Scientific Limited Employee Stock Option Scheme 2026' for eligible employees.
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational efficiency of the newly merged entity and the impact of the leadership changes on R&D output. The current financials are heavily influenced by one-time merger costs, so core EBITDA margins in upcoming quarters will be the key metric to watch.
Viyash Scientific Q3 PAT at ₹485.2M; Completes Major Merger and Restates Financials
Viyash Scientific reported a consolidated revenue of ₹8,584 million for Q3 FY26, showing steady growth from ₹7,740.3 million in the restated previous year quarter. The company successfully completed its massive Composite Scheme of Amalgamation, leading to a restatement of historical financials to reflect the merged entity. Net profit for the quarter stood at ₹485.2 million, which was impacted by one-time exceptional merger-related expenses of ₹412.6 million. The board also approved a new ESOP scheme and restructured senior management to align with post-merger strategic objectives.
முக்கிய அம்சங்கள்
Revenue from operations grew to ₹8,584 million in Q3 FY26 compared to ₹7,740.3 million in Q3 FY25 (restated).Net Profit for Q3 FY26 reached ₹485.2 million, despite ₹412.6 million in exceptional merger-related costs.Issued 18.19 crore equity shares and 2.03 crore warrants as part of the amalgamation share exchange.9M FY26 consolidated revenue reached ₹25,003.5 million with a total PAT of ₹1,582.7 million.Introduced 'Viyash Scientific Limited ESOP Scheme 2026' and appointed new VPs for R&D and Quality.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to drive operational synergies following the completion of the large-scale merger. The restated financials provide a new baseline for performance, and the management restructuring suggests a shift toward aggressive growth in the API and Animal Health segments.
Viyash Scientific Q3 Revenue Rises 11% to ₹8,584 Million Post-Merger Integration
Viyash Scientific (formerly Sequent Scientific) reported a consolidated revenue of ₹8,584 million for Q3 FY26, an 11% increase over the restated ₹7,740.30 million in the same period last year. Net profit for the quarter stood at ₹485.20 million, up from ₹419.40 million YoY, despite incurring ₹412.60 million in exceptional expenses related to its massive amalgamation scheme. The company has successfully integrated multiple entities including Viyash Life Sciences and Symed Labs, leading to a significant restatement of historical financials to reflect the new corporate structure. The board also approved a new ESOP scheme and key senior management appointments to drive post-merger synergies.
முக்கிய அம்சங்கள்
Revenue from operations grew 10.9% YoY to ₹8,584 million in Q3 FY26.Consolidated Profit After Tax (PAT) reached ₹485.20 million compared to a restated ₹419.40 million in Q3 FY25.Exceptional items of ₹412.60 million were recognized during the quarter for amalgamation-related expenses.The company allotted 18.19 crore equity shares and 2.03 crore warrants as part of the merger share exchange.New Senior Management Personnel appointed in R&D, Quality, and Regulatory roles to align with post-merger strategic objectives.
👀 கவனிக்க வேண்டியவை
Investors should view the successful completion of the complex merger as a significant scale-up event that transforms the company's asset base. Monitor the next two quarters for margin expansion as operational synergies from the integrated entities begin to reflect in the bottom line.
Viyash Scientific Partners with Boehringer Ingelheim for India Companion Animal Portfolio
Viyash Scientific's subsidiary, Alivira Animal Health, has entered a strategic partnership with Boehringer Ingelheim India to distribute and promote their companion animal products. This collaboration aims to leverage Alivira's extensive distribution network across urban and rural India to capture the growing pet healthcare market. The announcement follows the recent completion of the merger and name change from Sequent Scientific to Viyash Scientific on January 8, 2026. This move strengthens Viyash's position in the high-margin companion animal segment by adding a global leader's innovative product pipeline to its portfolio.
முக்கிய அம்சங்கள்
Alivira Animal Health to distribute and promote Boehringer Ingelheim's companion animal portfolio in IndiaViyash Scientific is currently ranked among the top 25 animal health companies globally, serving over 100 countriesPartnership targets the rapidly growing Indian pet healthcare market driven by rising ownership and preventive care awarenessThe company officially transitioned from Sequent Scientific to Viyash Scientific on January 8, 2026, following a mergerViyash employs over 3,000 people and maintains manufacturing and R&D operations across India, Spain, Brazil, Turkey, and the USA
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from this partnership as it scales Viyash's domestic formulation business. The association with a global giant like Boehringer Ingelheim validates Viyash's distribution capabilities and enhances its strategic positioning in the animal health sector.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Viyash Scientific Announces CRISIL Rating Withdrawal for Symed Labs Post-Amalgamation
Viyash Scientific Limited (formerly Sequent Scientific) has announced that CRISIL has withdrawn the credit ratings for Symed Labs Ltd following its successful amalgamation into the parent group. Symed Labs, which reported a revenue of ₹785 crore and a PAT of ₹120 crore in FY25, has ceased to exist as a separate legal entity. The withdrawn ratings include 'CRISIL A/Watch Developing' and 'CRISIL A1' for bank facilities totaling approximately ₹182 crore. This withdrawal is a standard procedural step following the merger effective as of December 2025.
முக்கிய அம்சங்கள்
Symed Labs amalgamated with Viyash Lifesciences and subsequently with Sequent Scientific (now Viyash Scientific) in late 2025CRISIL withdrew ratings for ₹162 crore fund-based and ₹20 crore non-fund-based facilities at the company's requestSymed Labs reported strong FY25 financials with a PAT margin of 15.4% and revenue growth to ₹785 croreThe entity maintained a very healthy capital structure with an adjusted debt/networth ratio of 0.03 timesViyash Scientific is a Carlyle-backed pharmaceutical player with a global footprint in API and animal health
👀 கவனிக்க வேண்டியவை
This is a routine administrative update following a corporate restructuring; investors should focus on the consolidated financial performance of the merged Viyash Scientific entity. No change in the underlying credit strength is implied by this procedural withdrawal.
Sequent Scientific Shareholders Approve Name Change to Viyash Scientific with 99.99% Majority
Shareholders of Sequent Scientific Limited have overwhelmingly approved a special resolution to change the company's name to Viyash Scientific Limited. The proposal received 99.99% approval, with 174.26 million votes in favor and only 17,224 against. Additionally, shareholders approved the alteration of the company's Objects Clause in the Memorandum of Association. This rebranding follows the company's integration into the Viyash platform and marks a significant shift in corporate identity.
முக்கிய அம்சங்கள்
Special resolution for name change to Viyash Scientific Limited passed with 99.99% of valid votes.Alteration of the Objects Clause in the Memorandum of Association approved by 99.99% of voting shareholders.Promoter group showed 100% support for the resolutions, casting 131.68 million votes in favor.Public institutions also showed strong support with 89.98% participation and 100% votes in favor.The resolutions are deemed passed as of December 28, 2025, following the conclusion of the postal ballot.
👀 கவனிக்க வேண்டியவை
Investors should note the upcoming change in company name and potential ticker symbol update on BSE and NSE. While the rebranding reflects a new corporate phase, investors should continue to monitor the company's operational performance under the new identity.
CA Hull Investments Acquires 31.2% Stake in Sequent Scientific via Viyash Merger
Sequent Scientific has completed the allotment of equity shares following its composite scheme of amalgamation with Viyash Life Sciences and other entities. CA Hull Investments was allotted 13,61,60,231 shares, representing a 31.20% stake in the post-merger entity. This transaction brings the total promoter group holding, including CA Harbor Investments, to 61.4%. The allotment was executed based on a swap ratio of 56 Sequent shares for every 100 Viyash shares as approved by the NCLT.
முக்கிய அம்சங்கள்
Allotment of 13,61,60,231 equity shares to CA Hull Investments following the Viyash merger.CA Hull Investments now holds a 31.20% stake in Sequent Scientific.Total promoter group holding increased to 61.4% in the expanded equity base.Share exchange ratio set at 56 Sequent shares (FV ₹2) for every 100 Viyash shares (FV ₹10).The merger was sanctioned by the NCLT Hyderabad bench vide order dated November 18, 2025.
👀 கவனிக்க வேண்டியவை
Investors should view the completion of this merger as a significant scale-up event for Sequent Scientific. Monitor upcoming quarterly results for operational synergies and the impact of Viyash's integration on the consolidated bottom line.
Sequent Scientific has finalized its composite scheme of amalgamation, effectively merging Viyash Life Sciences and several other entities into the company. As part of the deal, Sequent allotted 18.19 crore new equity shares to Viyash shareholders at a swap ratio of 56:100, increasing the total paid-up capital to Rs 87.21 crore. The company also issued 2.03 crore share warrants at Rs 181.94 each, receiving an upfront payment of Rs 92.52 crore. A significant leadership change accompanies the merger, with industry veteran Dr. Haribabu Bodepudi appointed as the new Managing Director and Group CEO.
முக்கிய அம்சங்கள்
Allotment of 18,19,21,827 equity shares to Viyash shareholders at a ratio of 56 Sequent shares for every 100 Viyash shares.Total paid-up equity capital increased from Rs 50.82 crore to Rs 87.21 crore, representing a ~71.6% expansion.Issuance of 2.03 crore share warrants at Rs 181.94 per warrant, with Rs 92.52 crore (25%) received upfront.Appointment of Dr. Haribabu Bodepudi (former Mylan India CEO) as MD and Group CEO for a 2-year term.CA Hull Investments officially inducted as a promoter, and Appco Pharma LLC becomes a material subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should view this as a transformative growth move that expands Sequent's scale and leadership depth, though they must factor in the significant equity dilution. Monitor the integration of Viyash's API and formulation assets for realized synergies in upcoming quarterly results.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
